http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Sat, 21 Oct 2017 02:35:44 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Cholesterol drug failures spark big pharma interest in Optibiotix's microbiome-based alternative ]]> http://www.proactiveinvestors.co.uk/companies/news/185799/cholesterol-drug-failures-spark-big-pharma-interest-in-optibiotix-s-microbiome-based-alternative-185799.html Microbiome specialist Optibiotix PLC (LON:OPTI) has seen a marked increase in cholesterol lowering product LP-LDL from ‘big pharma’ after another high profile development failure.

Merck pulled the plug on its cholesterol lowering drug Anacetrapib last week after disappointing trial results.

Pfizer had already scrapped a similar protein inhibiting product, bococizumab in December, while Roche, Bristol-Myers Squibb and Eli Lilly have all suffered disappointments in this area.

Stephen O’Hara, Optibiotix’s chief executive, said the failures of these drugs had sparked interest in a possible combination with LP-LDL its own natural cholesterol reducing product.

The problems with these failings in high cost drug development is that it limits the therapeutic options, he told Proactive.

“This is increasing pharma’s interest in safe proven natural alternatives like LP-LDL to supplement and extent the patent life of existing drugs with combination therapies.“

Optibiotix had seen big pharma interest “build” over the past 3-4 months following Pfizer’s move and he expects this to grow as “The interface between food and pharmaceuticals narrows.”

A food additive, LP-LDL‘s efficacy is at a similar level to pharmaceutical products but with fewer side effects.

Any collaboration would likely take the form of a licensing/joint venture deal.

Anecdotally, LP-LDL is also showing good efficacy in reducing blood pressure as well as lowering cholesterol, said O’Hara.

One example, on the Optibiotix website, cites a person in their fifties who saw their blood pressure reduce more by using LP-LDL than through the ACE Inhibitor they had been prescribed. ACE Inhibitors are drugs designed to lower blood pressure by reducing angiotensin II in the body.

While this was only one person, O’Hara added that its own research had indicated a similar group effect on blood pressure and cholesterol across a much wider population (young, old, men and women,) and in much higher population numbers.

“It also shows the higher the blood pressure or cholesterol the greater the effect so the benefits are greatest in those most in need. “ 

A noticeable beneficial effect on hypertension (high blood pressure) would be a significant differentiator for LP-LDL, O’Hara said, and if possible it will try to find a partner to carry out further clinical studies.

OptiBiotix has been a pioneer of products based around the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food and that had led to a range of products being developed by the company that are now approaching the commercial stage.

The strategy so far has been to find commercial rather than research partners.

A memorandum of understanding has already been signed with Bened to explore opportunities to combine LP-LDL with the Taiwanese firm’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies.

Industry leaders Tata Chemical and pro-biotics specialist Sacco have also all recently agreed deals for a variety of Optibiotix’s products.

Tata’s deal was for appetite suppressant Slimbiome. A new version of the flour-like weight loss additive was launched in the US at Las Vegas last month.

]]>
Wed, 18 Oct 2017 11:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/185799/cholesterol-drug-failures-spark-big-pharma-interest-in-optibiotix-s-microbiome-based-alternative-185799.html
<![CDATA[News - US launch of new microbiome products generates plenty of interest, says Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/news/185030/us-launch-of-new-microbiome-products-generates-plenty-of-interest-says-optibiotix-185030.html OptiBiotix Health PLC (LON:OPTI) has launched its SlimBiome and LP products in the US at the Supply Side West trade show.

Both products recently received FDA registration and the presentation at Supply Side West was the first in a number of steps to attract food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market.

READ: Optibiotix Health lines up the targets for its “Precision microbiome engineering”

Cholesterol reducer LP was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, while appetite suppressant SlimBiome was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. 

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries with high interest from around the world, said the company.

Additionally, Optibiotix said that Sacco has appointed Dr Lucio Lepera as product manager for LP’s entry into the US probiotic market and extend it into the dairy market.

READ: OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara

Cereal Ingredients, meanwhile, has incorporated SlimBiome into its range of cereal-based particulates and speciality ingredients that includes bakery products, breakfast cereals, crackers, toppings, products that extend it into the nutraceutical, health and wellbeing industry sectors. 

Stephen O'Hara, OptiBiotix’s chief executive, said in a statement: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. 

He added looking for partners was a low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products.

]]>
Wed, 04 Oct 2017 08:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/185030/us-launch-of-new-microbiome-products-generates-plenty-of-interest-says-optibiotix-185030.html
<![CDATA[RNS press release - Successful launch of products at Supply Side West ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171004070007_13385059/ Wed, 04 Oct 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171004070007_13385059/ <![CDATA[News - Optibiotix Health lines up the targets for its “Precision microbiome engineering” ]]> http://www.proactiveinvestors.co.uk/companies/news/184447/optibiotix-health-lines-up-the-targets-for-its-precision-microbiome-engineering-184447.html Stephen O’Hara, Optibiotix Health PLC's (LON:OPTI) chief executive, believes his company will have ‘many shots on goal’ in the coming years as it develops its range of products based around the human microbiome.

The company has scored once already with the recent float of SkinBioTherapeutics PLC (LON:STBX), a company that has grown in value from around £400,000 to £11mln and an AIM listing in little more than a year.

Now the plan is to repeat the formula with the group’s three other divisions.

Microbiome pioneer

OptiBiotix has been a pioneer of the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food and that had led to a range of products being developed by the company that are now approaching the commercial stage.

O’Hara says it can use bacteria to build complex sugars that act like fibres, which allows it change the microbiome in a very targeted way.

“Precision microbiome engineering” is what O’Hara calls it and it’s a phrase he says the market is going to be hearing much more of in future.

Separate listings 

O’Hara sees potential for each of its weight loss, pro-biotics and sugars operations, and indeed Skinbiotherapeutics where it still has a 42% stake, to match Optibiotix’s current market value. 

The process of separating the three divisions along the lines of SkinBiotherapeutics has already started with Optibiotix also beefing up the commercial capability of each.

Eventually that may see further separate listings or even a Nasdaq listing for the whole group.

“We were a science company, now we are a commercial company with proven technologies and proven products in the market place.”

Products now the focus

Industry leaders Tata Chemical, pro-biotics specialist Sacco and Bened in Asia have all recently agreed deals for a variety of Optibiotix’s products.

Tata’s deal was for appetite suppressant Slimbiome. A  new version of the flour-like weight loss additive will be launched in the US at Las Vegas this week while a backlog of orders has built up from the earlier VitaFoods exhibition in Europe.

The upgrade makes its easier to mix, easier to dissolve and ensures better flavours opening up markets such as gym users who want a shake and bakeries that can fold it in for bread.

O'Hara says he had one order before the product had even gone on show at Vitafoods

Risk strategy pays off

When starting Optibiotix he knew working on the microbiome would be really exciting but to spread the risk, because it was so new, went for a number of different options.

“In three years in a new area of science, the microbiome, we’ve developed across four areas, developed 60 patents, twenty trademarks and are now starting to launch products.”

“We thought one or two might fail, but all have worked."

At 65.2p, Optibiotix is valued at £51.4mln.

]]>
Fri, 22 Sep 2017 11:41:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/184447/optibiotix-health-lines-up-the-targets-for-its-precision-microbiome-engineering-184447.html
<![CDATA[Media files - OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8105/optibiotix-gaining-real-commercial-traction-ceo-stephen-o-hara-8105.html Tue, 19 Sep 2017 15:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/8105/optibiotix-gaining-real-commercial-traction-ceo-stephen-o-hara-8105.html <![CDATA[News - Optibiotix Health to launch improved version of weight loss product Slimbiome ]]> http://www.proactiveinvestors.co.uk/companies/news/184189/optibiotix-health-to-launch-improved-version-of-weight-loss-product-slimbiome-184189.html OptiBiotix Health plc (LON:OPTI) is to launch an improved version of its hunger suppressant/weight loss product Slimbiome at a major US trade fair at the end of the month.

The new formulation is a single homogenous product, a development that reduces separation in transport and makes it available in places such as in-store bakeries where previously it might have been difficult to blend or remix.

Solubility has also been improved, making it taste and fell better in existing products such as 'GoFigure' shakes and bars.

Improved dispersion in water will help open new markets, said Stephen O’Hara, chief executive as it makes it ideal for gym users who want to mix it into a liquid shake

The new formula will also be cheaper to produce as there is less waste.

Optibiotix already has US product registration for Slimbiome, which is a patented combination of natural ingredients, and will launch the new version at the Supply Side West trade show where it will be exhibited with Cereal Ingredients Inc, a potential joint development partner.

READ: OptiBiotix technology gaining commercial traction; more to come says broker

Cereal Ingredients is considering incorporating SlimBiome into a range of cereal based particulates and ingredients aimed at the nutraceutical, health and wellbeing sectors. 

Other manufacturers are looking at SlimBiome's possible application into 'Health & Wellbeing' food and beverage products.  

READ: OptiBiotix to hook-up with Bened Biomedical to open new routes into south-east Asia for its cholesterol reduction products

Optibiotix is also launching its LPLDL cholesterol and blood pressure lowering product at Supply Side West, which takes place in Las Vegas on 27-28 September. 

O'Hara added: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners.

“As we build the range of applications, products and geographic scope of SlimBiome with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products.”

House broker finncap said the new formula was further evidence of the commercial progress the company is making, with the fact that talks with under way with other potential partners (to add to recent deals with Sacco and Tata Chemical) an encouraging development.

Shares rose 0.5% to 67.9p.

--Adds broker comment, detail and share price--

]]>
Tue, 19 Sep 2017 07:30:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/184189/optibiotix-health-to-launch-improved-version-of-weight-loss-product-slimbiome-184189.html
<![CDATA[RNS press release - Technical, regulatory & commercial update ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170919070003_13366966/ Tue, 19 Sep 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170919070003_13366966/ <![CDATA[News - OptiBiotix technology gaining commercial traction; more to come says broker ]]> http://www.proactiveinvestors.co.uk/companies/news/183167/optibiotix-technology-gaining-commercial-traction-more-to-come-says-broker-183167.html OptiBiotix Health PLC (LON:OPTI) said its interim results charted a period of "significant” commercial  progress, including product launches and sales agreements.

Key among the deals inked was one with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

It is one of a number of pro-biotic products developed by the life sciences company that tackle obesity, high cholesterol and diabetes.

Sacco deal inked

LPLDL is another of its innovations that is gaining market traction. OptiBiotix struck a profit-sharing deal with Italian firm Sacco to manufacture and supply cholesterol-reducing compound and the first sales of the product were made to HLH BioPharma Vertriebs·    

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

Deals with Sacco and HLH, meanwhile, were expanded after the period-end, while in September the company signed a memorandum of understanding (MOU) with Bened Biomed that could open up markets in south-east Asia to the LPLDL strain. The MoU provides a 12-month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL strain and Bened’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies.

OptioBiotix said the agreement includes: the potential for Bened to commercialise OptiBiotix’s  LPLDL strain in Taiwan, Japan, Korea, and South East Asia; the potential for OptiBiotix to commercialise Bened’s PS128 strain in Europe and the USA; and the possibility of combining relevant assets to broaden the commercial offering and global reach

Positive financial performance

The financial performance of the company was positively impacted by the spin-off earlier this year of subsidiary Skinbiotherapeutics as a separate AIM-listed company valued at £4.5mln.

This resulted in a change in value of Opti’s investment in the business of £4.1mln. This adjustment led to the company posting a pre-tax profit of £3.2mln for the six months ended May.

CEO upbeat

Chief executive Stephen O’Hara was upbeat on what was achieved as well as the prospects for remainder of the financial year.

"OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base,” he said.

“This has stimulated industry interest from both national and multinational companies in selling our products in both consumer health and pharmaceutical markets around the world.

“The microbiome has been described by commentators as healthcare's 'most promising and lucrative frontier'.

“As OptiBiotix's microbiome modulating platforms generate products and multiple revenue streams from royalties and supply agreements, there is potential for a significant enhancement in the value of the company.”

Microbiome pioneer

OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes, as well as potential products for skin care.

Its LPLDL formulation comes from the bacterial species Lactobacillus plantarum.

Lactobacilli are common components of the human intestine and used by the food industry as probiotics.

Strong intellectual property

“[The] strong IP and broad portfolio is being shown to attract high calibre companies and, given the current rate of commercial deal signings, we anticipate current third-party interest to continue converting into licence deals, supply agreements and royalty revenues in the coming months,” said finnCap analyst Alex Pye in a note to clients.

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

Further spin-offs?

Having created value from the SkinBio spin-off, CEO O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

He said he hoped any listing would be planned sometime by the end of this year and the beginning of next, once each division has built up its IP, development programmes, and commercial partnerships.

The firm’s boss also said he plans to give some more of the value from the SkinBio float back to Opti shareholders in the future as well, in a way that is best for both firms.

Creating value

The aim, he said, is to further the commercialisation phase of the business, increasing revenues organically, but is also exploring the opportunity to make a strategic acquisition as well, which may be the only reason for the firm to raise any further cash, given its healthy balance sheet.

Certainly, Opti has provided shareholders with value thus far with the stock changing hands for 69p, compared with a flotation price in August 2014 of 8p a share.

If O’Hara and his team can deliver on his plans, that value could be very much enhanced.

]]>
Wed, 13 Sep 2017 12:07:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183167/optibiotix-technology-gaining-commercial-traction-more-to-come-says-broker-183167.html
<![CDATA[News - OptiBiotix to hook-up with Bened Biomedical to open new routes into south-east Asia for its cholesterol reduction products ]]> http://www.proactiveinvestors.co.uk/companies/news/183899/optibiotix-to-hook-up-with-bened-biomedical-to-open-new-routes-into-south-east-asia-for-its-cholesterol-reduction-products-183899.html OptioBiotix Health PLC (LON:OPTI) is planning to hook-up with Bened Biomedical of Taiwan to explore licensing and sales opportunities over the next 12 months.

The life sciences business focused on tackling obesity, high cholesterol and diabetes has signed a memorandum of understanding (MOU) with Bened.

The MoU provides a 12-month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL strain and Bened’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies. 

OptioBiotix said the agreement includes: the potential for Bened to commercialise OptiBiotix’s  LPLDL strain in Taiwan, Japan, Korea, and South East Asia; the potential for OptiBiotix to commercialise Bened’s PS128 strain in Europe and the USA; and the possibility of combining relevant assets to broaden the commercial offering and global reach

The Aim-listed firm said the partnership, should it come to fruition, would widen its probiotic portfolio into the area of psycho-biotics – where bacteria in the gut communicates with the brain (the “gut-brain axis”).

Referring to the “Microbiota-Gut-Brain Axis”, OptiBiotix said there is mounting evidence that suggests the microbiome helps shape neural development, brain biochemistry and behaviour.

New markets

The partnership would also open up commercial routes for the UK company into Asian markets, including Japan – the world's third largest dietary supplements market - with a total probiotic retail value of US$16.1bn, of which supplements account for US$700mln, according to Euromonitor International.

“We are pleased to announce this strategic partnership with Bened Biomedical and see a strong rationale for both companies to work together based on a complementary understanding of the science in different application areas of the microbiome," said Stephen O'Hara, chief executive officer of OptiBiotix.

“We are excited by recent advances in psycho-biotics which have the potential to address a range of mental and emotional health issues such as anxiety, depression, autism and Parkinson’s. We strongly believe Bened’s scientific and commercial capabilities in psychobiotics creates potential for OptiBiotix to bring new products to new markets and extend both our product offering and global reach in the microbiome field to bring better science and better health to all,” he added.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US next month

Frankie Cheng, chief executive of Bened Biomedical, was similarly effusive about the possibilities of the partnership.

"OptiBiotix operates in a very exciting and progressive area that has the potential to bring real health benefits,” he said.

“It has exciting products with strong science and clinical studies which we believe can be commercialised successfully through our distribution capability. We see mutual benefit in OptiBiotix’s commercial advances in Europe and US as a way to bring our PS128 product to a wider audience,” he added.

Summing things up, OptiBiotix's house broker, finnCap, said: “Geographically, OPTI will benefit by potentially going on to commercialise LP-LDL into Taiwan, Japan, Korea and SE Asia, whilst Bened could benefit through OPTI commercialising its PS128 strain in Europe and the US.”

“The widening of OPTI's probiotic portfolio into psychobiotics allows for wider potential markets opportunities going forward and is positive, given that Bened is established in this area as a market leader,” said analysts Alex Pye and Mark Brewer.

Bened Biomedical is a Taiwanese probiotic company whose patented product PS128 already has sales (including online) and is sold internationally in over ten countries, finnCap noted.

Earlier animal studies for PS128 have shown encouraging results in reducing anxiety and depression, it added.

Shares in OptiBiotix rose 0.6% to 69.89p in a falling market on the news.   

READ: OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals ]]>
Wed, 13 Sep 2017 08:52:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183899/optibiotix-to-hook-up-with-bened-biomedical-to-open-new-routes-into-south-east-asia-for-its-cholesterol-reduction-products-183899.html
<![CDATA[RNS press release - Strategic partnership with Bened Biomedical ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170913070003_13360669/ Wed, 13 Sep 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170913070003_13360669/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170911120001_13358413/ Mon, 11 Sep 2017 12:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170911120001_13358413/ <![CDATA[RNS press release - Invited to present at Expoquimia in Barcelona ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170907070007_13354508/ Thu, 07 Sep 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170907070007_13354508/ <![CDATA[RNS press release - Investor evening ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170906093001_13353332/ Wed, 06 Sep 2017 09:30:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170906093001_13353332/ <![CDATA[Media files - Optibiotix signs 'very good' manufacturing deal with Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8033/optibiotix-signs-very-good-manufacturing-deal-with-tata-chemicals-8033.html Tue, 05 Sep 2017 14:17:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/8033/optibiotix-signs-very-good-manufacturing-deal-with-tata-chemicals-8033.html <![CDATA[News - OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/news/183431/optibiotix-inks-sweet-manufacturing-deal-with-indian-food-ingredients-giant-tata-chemicals-183431.html Life sciences group OptiBiotix Health plc (LON:OPTI) has signed a manufacturing agreement with India-listed food ingredients giant Tata Chemicals.

It is an expansion of a deal the two inked last December and gives Tata, part of the Tata Group, the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain.

WATCH: Opti boss on 'very good' deal with Tata READ: Opti partners up with multinational as it targets Asian weight loss markets

The sugar – galacto-oligosaccharide – will be used in various food and over-the-counter products, subject to its successful development at pilot development.

When digested they stimulate the growth of ‘good’ gut bacteria, which Opti has showed can lead to improved health and help to tackle ‘chronic lifestyle diseases’ such as diabetes and obesity.

This agreement with Tata focuses on the Asian markets, particularly India, but Opti is in talks with other companies about manufacturing the cholesterol and blood pressure-lowering strain in other markets such as the US.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US soon

“We believe the combination of OptiBiotix's ability to develop ingredients which can modify an individual's microbiome, and Tata's research and manufacturing expertise, international reputation, and global reach, places both companies at the forefront of global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“This agreement takes both companies further down the path of translating the science of the microbiome field into products which will improve the health and wellbeing of people around the world.”

City broker praises 'interesting' deal

"The announcement is interesting in that TATA recently launched its own GOS related first general health product and is a major supplier of pharmaceutical industries both within India and globally," said finnCap analyst Lorne Daniel.

"Whilst only in the earliest stages of development, we are encouraged by this announcement and continue to recognise the commercial milestones that OPTI's management are steadily and reliably delivering upon."

Shares rose 5.35%, or 3.8p, to 74.8p.

--Updates for broker comment, video link and share price--

]]>
Tue, 05 Sep 2017 07:45:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183431/optibiotix-inks-sweet-manufacturing-deal-with-indian-food-ingredients-giant-tata-chemicals-183431.html
<![CDATA[RNS press release - Manufacturing Agreement with Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170905070001_13351538/ Tue, 05 Sep 2017 07:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170905070001_13351538/ <![CDATA[RNS press release - Exercise of Options and Issue of Equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170901144145_13349451/ Fri, 01 Sep 2017 14:41:45 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170901144145_13349451/ <![CDATA[News - OptiBiotix interims chart a period of significant commercial progress ]]> http://www.proactiveinvestors.co.uk/companies/news/183145/optibiotix-interims-chart-a-period-of-significant-commercial-progress-183145.html OptiBiotix Health PLC (LON:OPTI) said its interim results charted a period of "significant” commercial  progress, including product launches and sales agreements.

The life sciences company is developing pro-biotic compounds that tackle obesity, high cholesterol and diabetes.

READ:OptiBiotix set to launch its cholesterol-reducing strain in US next month

Key among the deals inked was one with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

Sacco deal inked

It also has a profit-sharing deal with Italian firm Sacco to manufacture and supply OptiBiotix's cholesterol-reducing strain, LPLDL. The first sales of this particular product were made to HLH BioPharma Vertriebs.    

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

Deals with Sacco and HLH, meanwhile, have been expanded since the period-end.

WATCH: Optibiotix broadens tie-up with Sacco to cover US and rest of the world

The financial performance of the company was positively impacted by the spin-off earlier this year of subsidiary Skinbiotherapeutics as a separate AIM-listed company valued at £4.5mln.

This resulted in a change in value of Opti’s investment in the business of £4.1mln. This adjustment led to the company posting a pre-tax profit of £3.2mln for the six months ended May.

CEO upbeat

Chief executive Stephen O’Hara was upbeat on what was achieved as well as the prospects for remainder of the financial year.

"OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base,” he said in a statement.

“This has stimulated industry interest from both national and multinational companies in selling our products in both consumer health and pharmaceutical markets around the world.

“The microbiome has been described by commentators as healthcare's 'most promising and lucrative frontier'.

“As OptiBiotix's microbiome modulating platforms generate products and multiple revenue streams from royalties and supply agreements, there is potential for a significant enhancement in the value of the company.”

]]>
Wed, 30 Aug 2017 07:24:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183145/optibiotix-interims-chart-a-period-of-significant-commercial-progress-183145.html
<![CDATA[RNS press release - Half-year Report ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170830070002_13344905/ Wed, 30 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170830070002_13344905/ <![CDATA[News - OptiBiotix set to launch its cholesterol-reducing strain in US next month ]]> http://www.proactiveinvestors.co.uk/companies/news/182913/optibiotix-set-to-launch-its-cholesterol-reducing-strain-in-us-next-month-182913.html OptiBiotix Health PLC (LON:OPTI) saw its shares gain today on news it is set to launch its LPLDL cholesterol and blood pressure lowering strain in the United States next month.

In late afternoon trade, Optibiotix shares were ahead 5%, or 3.5p at 73.0p.

WATCH Milestone for Optibiotix with first sales in Germany of LPLDL capsules

In a note to clients, analysts at finnCap said: “The US is one of the largest and fastest-growing probiotic markets in the world, with expected sales of $3.3bn in 2021.

“Following on from the recent expansion of OPTI's manufacturing and supply agreement with Sacco, this is yet another example of the commercial development and industry awareness of the LP-LDL brand.”

News of the Stateside launch comes just days after Opti announced a global manufacturing and supply agreement with Italian food company Sacco.

The two – Opti and Sacco – will co-exhibit at the Supply Side West trade show in Las Vegas at the end of September, where they will present various products that contain the LPLDL strain.

Significant progress in raising industry awareness 

Among the products they’ll be showing off will be CholBiome and CardioBiome – both of which contain the LPLDL strain – as well as some new concepts.

“OptiBiotix has made significant progress in raising industry awareness of its LPLDL strain,” said chief executive Stephen O’Hara.

“This has created a high level of interest in commercialising products containing LPLDL as a component in higher value branded products in markets globally.”

“Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners.”

Latest step in building global profile of LPLDL

OptiBiotix has previously taken various steps to build the profile of LPLDL in Europe, including a non-exclusive licence agreement with Italy-based food supplements provider, Nutrilinea.

It said that the upcoming launch in Las Vegas would be the “first of a number of steps taken” to get partners from the US on board.

The US probiotic market will be key for OptiBiotix going forward, given its size and the rate at which it is growing. Supplements alone generated more than US$2bn in sales last year, while experts reckon that will grow to US$3.3bn by 2021.

With Europe and the US almost ticked off the list, the AIM-quoted group said it is in discussions with possible corporate partners for the manufacture and distribution of products containing LPLDL in the Asian and other international markets.

 -- Adds share price, analyst comment --

]]>
Thu, 24 Aug 2017 07:46:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/182913/optibiotix-set-to-launch-its-cholesterol-reducing-strain-in-us-next-month-182913.html
<![CDATA[RNS press release - US product launch of LPLDL® at trade show ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170824070002_13340075/ Thu, 24 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170824070002_13340075/ <![CDATA[Media files - Optibiotix broadens tie-up with Sacco to cover US and rest of the world ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7974/optibiotix-broadens-tie-up-with-sacco-to-cover-us-and-rest-of-the-world-7974.html Tue, 22 Aug 2017 12:20:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7974/optibiotix-broadens-tie-up-with-sacco-to-cover-us-and-rest-of-the-world-7974.html <![CDATA[News - OptiBiotix Health expands its supply agreement with Italian food company ]]> http://www.proactiveinvestors.co.uk/companies/news/182783/optibiotix-health-expands-its-supply-agreement-with-italian-food-company-182783.html OptiBiotix Health PLC (LON:OPTI) has announced an expansion of a key manufacturing and supply agreement.

It is broadening its European tie-up with Italian food company Sacco, signed in March, to cover the US and rest of the world.

WATCH: Optibiotix broadens tie-up with Sacco to cover US and rest of the world

The deal gives Sacco the exclusive right to manufacture and supply OptiBiotix's cholesterol and blood pressure reducing LPLDL bacterial strains in the new territories.

Sacco will receive 50% of all profits and the two have agreed a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting.

READ: Milestone for Optibiotix with first sales in Germany of LPLDL capsules Big market

The food additive can now be sold in America, the world’s largest probiotic market with annual sales of US$7.1bn. The new supply agreement will also see an extension of the LPLDL technology into dairy applications, which is a US$35.5bn market.

As important are the synergies from transaction with the economies of greater scale kicking in. It will also ensure long-term security of supply with Sacco's ability to produce at different locations from multiple facilities.

"This new agreement significantly extends the scale of the commercial opportunity open to LPLDL to new application areas and territories, and reflects growing confidence from both companies in LPLDL's market potential,” said chief executive Stephen O’Hara.

READ: FinnCap expects more deals to follow OptiBiotix's latest distribution deal

“We chose Sacco as we have been impressed by their ability to introduce LPLDL to a global network of distributors and believe extending our partnership with them provides the best opportunity of quickly building revenues and developing LPLDL into a global brand.

“In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners."

]]>
Tue, 22 Aug 2017 07:26:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/182783/optibiotix-health-expands-its-supply-agreement-with-italian-food-company-182783.html
<![CDATA[RNS press release - Global manufacturing & supply agreement with Sacco ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170822070002_13337186/ Tue, 22 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170822070002_13337186/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170731162730_13313763/ Mon, 31 Jul 2017 16:27:30 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170731162730_13313763/ <![CDATA[Media files - Milestone for Optibiotix with first sales in Germany of LPLDL capsules ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7840/milestone-for-optibiotix-with-first-sales-in-germany-of-lpldl-capsules-7840.html Wed, 26 Jul 2017 12:39:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7840/milestone-for-optibiotix-with-first-sales-in-germany-of-lpldl-capsules-7840.html <![CDATA[News - OptiBiotix passes major commercial milestone as cholesterol capsules go on sale in Germany ]]> http://www.proactiveinvestors.co.uk/companies/news/181454/optibiotix-passes-major-commercial-milestone-as-cholesterol-capsules-go-on-sale-in-germany-181454.html OptiBiotix Health PLC (LON:OPTI) has reached a significant milestone following the first sales in Germany of a new range of cholesterol-lowering capsules containing its breakthrough LP-LDL technology.

It follows the successful registration by partner HLH Biopharma (HLH) of the product, known as Lactobact, which uses naturally occurring strains of bacteria.

“We hope this will be the first of many product launches of multiple formulations and presentations of LP-LDL as the active component in a wide range of pharmaceutical and consumer products around the world,” said chief executive Stephen O’Hara.

WATCH: Milestone for Optiobiotix with first sales in Germany of LPLDL capsules

“HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. 

“Establishing early sales of LP-LDL to pharmacies with HLH helps substantiate the credibility in the science behind LP-LDL to build the brand and acceptance in the larger consumer healthcare markets."

Pioneer

OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes, as well as potential products for skin care.

Its LP-LDL formulation comes from the bacterial species Lactobacillus plantarum.

Lactobacilli are common components of the human intestine and used by the food industry as probiotics.

Unique line selected

LP-LDL is unique in that it was selected using OptiBiotix's Optiscreen platform from a collection of over 4,000 candidates for its “outstanding capacity” to hydrolyse bile salts.

This activity is crucial for both bacterial survival in the gut and its use to prevent and manage a number of health conditions such as high cholesterol, high blood pressure, glucose and energy regulation, vitamin metabolism, and liver function.

This creates the potential to use LP-LDL as the technology core of multiple products using the model pioneered by chipmaker Intel.

Broker expects more deals

The broker finnCap said revenues from Germany will be in the “low to mid six figures”.

Analyst Alex Pye expects further deals. “Management continues to deliver on key commercial milestones laid out at the time of our initiation,” he said.

“We expect OptiBiotix to continue to announce further supply agreements in the coming months with national pharmacies and large global consumer health partners.”

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

The firm already has commercial partners in place for all its platforms with global brands.

At the end of 2016, Opti partnered with Indian giant Tata to develop various weight management foods and products that contain its SlimBiome technology.

In March 2016, OptioBiotix also signed a deal with Sacco, one of Europe’s leading probiotic manufacturers and raw ingredients suppliers to manufacture and supply OptiBiotix's cholesterol reducing strain, LP-LDL, in Europe.

To give an idea of the size of the markets Opti is working in, finnCap estimates the functional (diet) foods market is worth £154bn annually.

Further action

Having created value from the SkinBio spin-off, O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

O’Hara said he hoped any listing would be planned sometime by the end of this year and the beginning of next, once each division has built up its IP, development programmes, and commercial partnerships.

The firm’s boss also said he plans to give some more of the value from the SkinBio float back to Opti shareholders in the future as well, in a way that is best for both firms.

Overall, O’Hara’s aim is to further the commercialisation phase of the business, increasing revenues organically, but is also exploring the opportunity to make a strategic acquisition as well, which may be the only reason for the firm to raise any further cash, given its healthy balance sheet.

Certainly, Opti has provided shareholders with value thus far with the stock changing hands for 66p, compared with a flotation price in August 2014 of 8p a share.

If O’Hara and his team can deliver on his plans, that value could be very much enhanced.

]]>
Wed, 26 Jul 2017 07:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/181454/optibiotix-passes-major-commercial-milestone-as-cholesterol-capsules-go-on-sale-in-germany-181454.html
<![CDATA[RNS press release - Market launch for LPLDL® capsules in Germany ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170726070002_13307333/ Wed, 26 Jul 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170726070002_13307333/ <![CDATA[News - FinnCap expects more deals to follow OptiBiotix's latest distribution deal ]]> http://www.proactiveinvestors.co.uk/companies/news/180959/finncap-expects-more-deals-to-follow-optibiotix-s-latest-distribution-deal-180959.html OptiBiotix Health plc (LON:OPTI) has signed a supply deal covering New Zealand and Australia with Pharmabiota.

The New Zealand-based firm, which has a growing retail pharmacy partner network throughout New Zealand and Australia, has committed to an initial purchases of 10,000 boxes each of three different products from OptiBiotix, each of which contains the company’s LPLDL technology, which is designed to reduce “bad” cholesterol.

OptiBiotix said the agreement would initially provide moderate levels of income, rising to six figures in the second year.

Pharmabiota has committed to growing orders by 10%.

READ Supply agreement with HLH Biopharma suggests strong demand for OptiBiotix's anti-cholesterol technology

Pharmabiota is not the first distributor to show an interest in OptiBiotix’s technology, but it is the first one outside Europe.

“We see this as another step in the company’s strategy of building multiple revenue streams from LPLDL ingredient supply (from our profit share with Sacco), and as a component in high-value white-label and branded formulations, across a range of national pharmacy and large consumer health international partners,” said Stephen O’Hara, the chief executive officer of OptiBiotix.

“This is a low risk, low cost approach, to accessing multiple consumer healthcare and pharmaceutical markets around the world. We are at the start of the commercialisation process but are really excited at the high level of interest in our products and the prospect of building multiple revenue streams, which if this strategy is successful, have the potential to cumulatively generate substantive seven figure revenues in the forthcoming years,” he added.

House broker finnCap said minimum purchase orders of 30,000 units signal a significant step in the company’s strategy of expanding the global supply of LPLDL, and builds upon similar agreements within the European Union.

The broker’s forecasts are under review until it gets revenue clarification, but it said it is encouraged by the momentum that appears to be growing in terms of multiple revenue streams for OptiBiotix.

The broker expects OptiBiotix to announce similar agreements in the coming months with national pharmacies and large global consumer health partners.

Shares in OptiBiotix were down 0.2% in mid-morning trading.

]]>
Mon, 17 Jul 2017 07:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/180959/finncap-expects-more-deals-to-follow-optibiotix-s-latest-distribution-deal-180959.html
<![CDATA[RNS press release - Supply agreement with Pharmabiota Ltd ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170717070003_13296467/ Mon, 17 Jul 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170717070003_13296467/ <![CDATA[Media files - Zak Mir expects OptiBiotix to trade in current range for time being ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7774/zak-mir-expects-optibiotix-to-trade-in-current-range-for-time-being-7774.html Tue, 11 Jul 2017 10:15:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7774/zak-mir-expects-optibiotix-to-trade-in-current-range-for-time-being-7774.html <![CDATA[News - Optibiotix’s SweetBiotix sugar substitute gets thumbs up from taste testers ]]> http://www.proactiveinvestors.co.uk/companies/news/180677/optibiotixs-sweetbiotix-sugar-substitute-gets-thumbs-up-from-taste-testers-180677.html OptiBiotix Health PLC’s (LON:OPTI) calorie-free sugar substitute, SweetBiotix, has been given the thumbs up from expert taste testers at the University of Reading.

Ten experienced panellists from the Flavour and Sensory Science Centre at the University of Reading tested six customised oligosaccharides developed from high intensity sweeteners.

WATCH: Zak Mir on Optibiotix

They found that the customised oligosaccharides showed sweetness of between 140x and 223x that of sucrose at equivalents, while the oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness.

Opti has often repeated its claim that its SweetBiotix technology has the potential to address public health concerns over the impact of sugar on obesity. As the natural SweetBiotix fibres are not digested in the human gut, they are calorie-free.

Concerns over sugar and artificial sweeteners

“We are really pleased with the results of this study which opens up opportunities for the development of a range of natural sweet prebiotic fibres which can be used to replace sugar in food and beverages,” said chief executive Stephen O’Hara.

“These may be classified as dietary fibres, which from an industry and consumer perspective, creates the prospect of substituting high calorie sugars with sweet healthy fibres.

“With growing public and political concerns over traditional sugars and artificial sweeteners OptiBiotix is leading research in an area of growing industry interest.”

Patent applications

Given that the global sweetener market, currently dominated by sugar, is expected to hit US$121bn by 2022, OptiBiotix is set to file for additional patents to further protect its existing intellectual property.

Shares edged 3.1% higher in early deals on Tuesday to 66p.

--Updates for share price--

]]>
Tue, 11 Jul 2017 09:05:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/180677/optibiotixs-sweetbiotix-sugar-substitute-gets-thumbs-up-from-taste-testers-180677.html
<![CDATA[RNS press release - SweetBiotix® development: Results of taste study ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170711070002_13290214/ Tue, 11 Jul 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170711070002_13290214/ <![CDATA[RNS press release - Grant of Options ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170706070006_13285573/ Thu, 06 Jul 2017 07:00:06 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170706070006_13285573/ <![CDATA[RNS press release - Result of AGM ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170615123032_13261918/ Thu, 15 Jun 2017 12:30:32 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170615123032_13261918/ <![CDATA[News - Supply agreement with HLH Biopharma suggests strong demand for OptiBiotix's anti-cholesterol technology ]]> http://www.proactiveinvestors.co.uk/companies/news/179291/supply-agreement-with-hlh-biopharma-suggests-strong-demand-for-optibiotix-s-anti-cholesterol-technology-179291.html OptiBiotix Health plc (LON:OPTI), the life sciences firm focused on obesity and skincare, has signed up HLH Biopharma GmbH as a customer.

HLH, which has more than 20 years of experience distributing probiotic and natural products under the brand names Lactobact and Casa Sana, has entered into a three-year agreement to produce, package and commercialise products containing OptiBiotix’s cholesterol-reducing LPLDL strain.  

The agreement follows HLH’s order for 100,000 capsules, announced at the end of April.

READ OptiBiotix sells batch of pre-launch LPLDL capsules to German distributor READ Materialising value for shareholders is the mantra for the boss of life sciences firm Optibiotix

This agreement provides a mutual commercial commitment with ongoing revenue and reflects the growing confidence in the science behind LPLDL as a functional component and its future brand value in a wide range of consumer healthcare and pharmaceutical products, OptiBiotix claimed. 

"We are pleased to announce this three year supply agreement with HLH, which demonstrates an ongoing financial commitment in building the brand from one of Europe's leading suppliers of probiotics to the pharmacy market,” said Stephen O’Hara, chief executive officer of OptiBiotix.

“We see this as an important next step in building stable long-term revenues and increased brand recognition of LPLDL,” he added.

O’Hara has previously spoken of emulating the “Intel inside” model, where the presence of a branded component in a product adds to the commercial allure of a product, and this agreement is a major step forward in terms of establishing LPLDL as a differentiating component of cardiovascular health products.

“We anticipate this is the first of many opportunities for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets," O’Hara said.

“Whilst no financial details are disclosed at this time, we understand that HLH’s decision to increase its financial commitment for LP-LDL is due to greater than anticipated product interest,” revealed OptiBiotix’s house broker, finnCap.

“Whilst we hold off issuing forecasts at this time, we are encouraged by OPTI's progress to date and management’s continued delivery on key commercial milestones laid out at the time of our initiation,” the broker added.

Shares in OptiBiotix were 2.1% higher at 73p in lunchtime trading.

---adds broker comment and updates share price---

]]>
Thu, 15 Jun 2017 12:04:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/179291/supply-agreement-with-hlh-biopharma-suggests-strong-demand-for-optibiotix-s-anti-cholesterol-technology-179291.html
<![CDATA[RNS press release - Supply agreement with HLH Biopharma GmbH ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170615070002_13260912/ Thu, 15 Jun 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170615070002_13260912/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170531070006_13243183/ Wed, 31 May 2017 07:00:06 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170531070006_13243183/ <![CDATA[News - OptiBiotix excited at high level of interest in its products ]]> http://www.proactiveinvestors.co.uk/companies/news/177838/optibiotix-excited-at-high-level-of-interest-in-its-products-177838.html Life sciences group OptiBiotix Health plc (LON:OPTI) has told investors that its health supplements were a massive hit when they were launched at the Vitafoods Europe tradeshow in Geneva last week.

Opti said it has already received draft contracts from several companies at the fair which are interested in selling its products; including its CholBiome, CardioBiome and SlimBiome supplements.

The products were exhibited in the New Products zone, as well as at the stands of AIM-quoted Opti’s European manufacturing and formulation partners, Sacco and Nutrilinea.

Interest expected to turn into revenues

“We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products,” said chief executive Stephen O’Hara.

“This has already resulted in some companies sending through draft contracts.

“The company anticipates that this interest will start to generate revenues from both ingredient supply, and as a component in high value white label and branded formulations and presentations, across multiples territories.”

CholBiome and CardioBiome both contain OptiBiotix’s LPLDL strain which has been shown to reduce cholesterol levels, blood pressure and cardiovascular risk.

SlimBiome on the other hand is its weight management technology. It increases the microbial diversity and number of healthy bacteria in your gut which improves a dieter’s chances of losing weight and then sustaining that weight loss.

Opti starting to commercialise its technology

In recent months the company has been working hard to commercialise its products and although it’s only at the start of this process, it’s already made decent progress.

Only last week OptiBiotix inked a non-exclusive agreement with Italy-based supplements provider Nutrilinea to produce, promote, market and commercialise health-focused products containing CholBiome and CardioBiome.

Back in March, the company also signed an exclusive deal with raw ingredients provider Sacco to manufacture and supply the LPLDL strain.

SlimBiome is a little bit further down the line; it has been used as a key ingredient in the GoFigure range of dieting products for some time.

The supplements are made by The Health Weight Loss Company – in which Opti has a 64% stake – and demand has been so strong that it recently had to pump in more money to help THWC keep up with demand.

OptiBiotix is also working on a calorie-free, naturally sweet fibre which it hopes will be a healthier alternative to sugar. UNlike a lot of similar products on the market, such as stevia, the company said there will be no taste trade-off.

]]>
Tue, 16 May 2017 07:42:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/177838/optibiotix-excited-at-high-level-of-interest-in-its-products-177838.html
<![CDATA[RNS press release - Successful launch of LPLDL and SlimBiome products ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170516070007_13226318/ Tue, 16 May 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170516070007_13226318/ <![CDATA[News - OptiBiotix nudges higher as it inks licence agreement for cholesterol-reducing strain ]]> http://www.proactiveinvestors.co.uk/companies/news/177501/optibiotix-nudges-higher-as-it-inks-licence-agreement-for-cholesterol-reducing-strain-177501.html OptiBiotix Health plc (LON:OPTI) has taken another step in building the profile of its LPLDL cholesterol-reducing strain after it inked a non-exclusive licence agreement with Italy-based food supplements provider, Nutrilinea.

The tie-up will see Nutrilinea produce, promote, market and commercialise OptiBiotix’s CholBiome and CardioBiome products – both of which contain the LPLDL strain – to its European network.

The AIM-quoted life sciences group said the agreement had been granted with a view to maximising the financial return for both parties.

It is the latest example of Opti’s strategy to bring together its science with an outside partner’s expertise and market reach.

Agreement will help develop LPLDL into a ‘global brand’

“We believe working with Nutrilinea, and similar partners around the world, provides the best opportunity of building LPLDL into a global brand,” said chief executive Stephen O’Hara.

“We see this as another step in building revenues and market presence of LPLDL as the 'Intel' inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world.”

Nutrilinea provides products containing some of the world’s best-selling probiotic strains to both national and international businesses in Europe and the US, OptiBiotix said.

It is “one of Europe’s fastest growing providers of food supplements” which has doubled its revenues over the past 12 months to over €30m per annum.

Shares gained 1.7p, or 2.5%, in early deals on Tuesday to trade at 70.2p.

--Updates for share price--

]]>
Tue, 09 May 2017 08:28:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/177501/optibiotix-nudges-higher-as-it-inks-licence-agreement-for-cholesterol-reducing-strain-177501.html
<![CDATA[RNS press release - LPLDL® Non-Exclusive European License Agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170509070007_13218357/ Tue, 09 May 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170509070007_13218357/ <![CDATA[News - OptiBiotix Health to present at prestigious probiotics and prebiotics conference in Budapest next month ]]> http://www.proactiveinvestors.co.uk/companies/news/177215/optibiotix-health-to-present-at-prestigious-probiotics-and-prebiotics-conference-in-budapest-next-month-177215.html Life sciences firm OptiBiotix Health plc (LON:OPTI) has had an abstract accepted for presentation at next month's International Scientific Conference on Probiotics and Prebiotics.

Taking place in Budapest, Hungary, from 20 June to 22 June, the conference is the world's largest scientific gathering of the movers and shakers in the field of probiotics (micro-organisms that are believed to provide health benefits when consumed) and prebiotics (substances that induce the growth or activity of micro-organisms) .

The conference attracts up to 500 leading scientists, opinion leaders, investors, and clinicians from more than 80 countries.

The abstract, titled “The Development of a Targeted Synergistic Synbiotic for Lactobacillus plantarum LPLDL”, describes how by combining its OptiScreen and OptiBiotic technology platforms, OptiBiotix was able to synthesise a dietary fibre that substantially enhances the cholesterol reducing activity of LPLDL in gut models. This creates the potential for next generation LPLDL products with cholesterol reduction levels potentially approaching those of statins.

CLICK HERE: For a daily round-up of all the Proactive news READ OptiBiotix sells batch of pre-launch LPLDL capsules to German distributor

LPLDL is a naturally-occurring strain of the bacterial species Lactobacillus plantarum. Lactobacilli are common components of the human intestine and are used by the food industry as probiotics for general health benefits.

"This abstract demonstrates the ability of OptiBiotix to create targeted prebiotics which when combined with a probiotic greatly enhances the probiotics growth and biological effect, in this case cholesterol reduction,” said Stephen O'Hara, chief executive officer of OptiBiotix. 

“This new research highlights the potential for the development of species or genera-specific probiotics to selectively enhance the growth and health benefits of existing probiotics. This has the potential to provide improved next generation products with enhanced performance and product differentiation in the probiotics functional food market, a market that is expected to be worth in excess of US$46.5bn by 2020,” he added.

CLICK HERE: For a daily round-up of all the Proactive news ]]>
Wed, 03 May 2017 07:42:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/177215/optibiotix-health-to-present-at-prestigious-probiotics-and-prebiotics-conference-in-budapest-next-month-177215.html
<![CDATA[RNS press release - Presentation of abstract at conference ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170503070012_13211852/ Wed, 03 May 2017 07:00:12 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170503070012_13211852/ <![CDATA[News - OptiBiotix sells batch of pre-launch LPLDL capsules to German distributor ]]> http://www.proactiveinvestors.co.uk/companies/news/176851/optibiotix-sells-batch-of-pre-launch-lpldl-capsules-to-german-distributor-176851.html Ahead of the launch of its LPLDL cholesterol-reducing strain next month, OptiBiotix Health plc (LON:OPTI) has sold a batch of capsules to a German distributor.

OptiBiotix said it has agreed to supply 100,000 units of LPLDL to HLH BioPharma Vertriebs, a company that has more than 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana.

HLH is one of Europe's leading suppliers of probiotics to the pharmacy market.

READ the OptiBiotix investment case WATCH OptiBiotix boss talk about the transition process

The bulk capsules will be packaged and branded as part of HLH's market leading Lactobact brand.

OptiBiotix said these pre-launch sales will provide moderate amounts of income for the group, and would raise industry awareness of LPLDL as a functional component in a wide range of consumer healthcare and pharmaceutical products.

"We see this as the first step in building sales and market presence of LPLDL as the 'Intel' inside a wide range of products for cardiovascular health across both consumer and pharmaceutical markets around the world,” explained Stephen O’Hara, chief executive officer of OptiBiotix.

“This creates the opportunity for multiple revenue streams from sales of the strain, white label, and branded products in different presentations and formulations to meet the needs of a diverse range of national and international markets," he added.

Shares in OptiBiotix were up 0.8% at 73.1p at midday after the release this morning of the company’s full year results.

SIGN UP to the Proactive Investors newsletter

 

 

]]>
Tue, 25 Apr 2017 12:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/176851/optibiotix-sells-batch-of-pre-launch-lpldl-capsules-to-german-distributor-176851.html
<![CDATA[RNS press release - First German sales ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170425085045_13203207/ Tue, 25 Apr 2017 08:50:45 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170425085045_13203207/ <![CDATA[News - OptiBiotix poised to make transition from technology company to revenue-generating producer ]]> http://www.proactiveinvestors.co.uk/companies/news/176824/optibiotix-poised-to-make-transition-from-technology-company-to-revenue-generating-producer-176824.html The next 12 months will see OptiBiotix Health plc (LON:OPTI) make the transition from a technology company to a product company.

The company said in its results statement covering 2016 that this year will see the microbiome specialist build revenue streams from a diverse range of products.

This process started in August 2016 with the launch of the company’s GoFigure products based on its SlimBiome platform and will continue next month with the launch of its LPLDL cholesterol reducing strain.

SIGN UP to the Proactive Investors newsletter READ the OptiBiotix investment case WATCH OptiBiotix boss talk about the transition process

Later this year, the company expects to launch the first generation of SweetBiotix, its natural sweet fibre to help with diabetes control.

The company now has an intellectual portfolio covering 50 patents across 15 product families; eight strain registrations and 16 trademarks.

OptioBiotix has a broad portfolio of intellectual property platforms

“OptiBiotix now has a broad portfolio of IP, multiple technology platforms, and an increasing range of products entering the market, and believes it is well placed to build on this solid foundation to build a microbiome business with significant future value for shareholders,” the company said.

Meanwhile, looking in the rear view mirror, the company saw a sharp increase in revenue in the year to 30 November 2016 but from a very small base. Revenue rose to £288,119 from £28,200 the year before.

The loss before tax was more or less steady at £1.52mln, compared to £1.42mln the year before.

SIGN UP to the Proactive Investors newsletter ]]>
Tue, 25 Apr 2017 07:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/176824/optibiotix-poised-to-make-transition-from-technology-company-to-revenue-generating-producer-176824.html
<![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170425070008_13202675/ Tue, 25 Apr 2017 07:00:08 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170425070008_13202675/ <![CDATA[News - Materialising value for shareholders is the mantra for the boss of life sciences firm Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/news/176222/materialising-value-for-shareholders-is-the-mantra-for-the-boss-of-life-sciences-firm-optibiotix-176222.html Materialising value for shareholders is the mantra for the boss of life sciences firm Optibiotix Health PLC (LON:OPTI), and the recent listing of its skin care business as SkinBioTherapeutics PLC (LON:SBTX) has helped kick that off handsomely.

SkinBioTheraputics made a strong debut when it floated on AIM last on April 5, with the shares rising from an offer price of 9p each to close at 13.25p on the first day of dealings, giving the new firm a value of around £14mln.

‘House’ broker FinnCap, which initiated coverage on Opti at the end of January, pointed out in a note that as it still owns a 41.9% stake in SkinBio after the float that represents around 7% of Opti’s current market cap of about £65mln.

Read: FinnCap has a good gut feeling … CLICK HERE: For a daily round-up of all the Proactive news …

The SkinBio business was created when Opti acquired exclusive rights to intellectual property developed by the University of Manchester around a year ago, and Opti injected £650,000 in to develop the business to give it a 77% holding prior to the float.

So Opti shareholders have clearly seen value created from that move, and chief executive Stephen O’Hara has plans to continue doing that.

O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body.

Microbiome model …

Opti is focused on using microbiome technology to tackle worldwide health issues such as obesity, high cholesterol and diabetes, and looks to partner up with food, health and pharma companies that have established routes to market to distribute its products.

With the SkinBio spin-off, the group is now focused on three development areas – OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

The firm already has commercial partners in place for all its platforms with global brands.

READ: OptiBiotix signs  profit-sharing deal with European manufacturer …

At the end of 2016, Opti partnered with Indian giant Tata to develop various weight management foods and products that contain its SlimBiome technology.

In March 2016, OptioBiotix also signed a deal with Sacco, one of Europe’s leading probiotic manufacturers and raw ingredients suppliers to manufacture and supply OptiBiotix's cholesterol reducing strain, LPLDL, in Europe.

While it waits to secure further deals, the company is on a steady financial footing. At the end of the last financial year, Opti had around £3mln in the bank and an annual cash burn of around £1.2mln.

To give an idea of the size of the markets Opti is working in, FinnCap analyst Alex Pye estimates that the functional (diet) foods market is worth US$200bn annually.

Further action …

Having created value from the SkinBio spin-off, O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

WATCH: Optibiotix CEO talks about 2017 focus …

O’Hara said he hoped any listing would be planned sometime by the end of this year and the beginning of next,  once each division has built up its IP, development programs, and commercial partnerships.

The firm’s boss also said he plans to give some more of the value from the SkinBio float back to Opti shareholders in the future as well, in a way that is best for both firms.

Overall, O’Hara’s aim is to further the commercialisation phase of the business, increasing revenues organically, but is also exploring the opportunity to make a strategic acquisition as well, which may be  the only reason for the firm to raise any further cash, give its healthy balance sheet.

Certainly, Opti has provided shareholders with  value, with the stock having jumped to a level of around 80p today against a flotation price in August 2014 of 8p a share.

If its boss can deliver on his plans that value could be very much enhanced.

CLICK HERE: For a daily round-up of all the Proactive news … ]]>
Sun, 16 Apr 2017 10:26:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/176222/materialising-value-for-shareholders-is-the-mantra-for-the-boss-of-life-sciences-firm-optibiotix-176222.html
<![CDATA[News - Optibiotix sees great opportunity in government's sugar reduction drive ]]> http://www.proactiveinvestors.co.uk/companies/news/175862/optibiotix-sees-great-opportunity-in-government-s-sugar-reduction-drive-175862.html New guidelines to cut the sugar content of sweets, chocolate, ice creams and breakfast cereals by 20% offer a tantalising opportunity for Optibiotix (LON:OPTI), its chief executive told Proactive investors.

Public Health England, the UK's well-being overseer, wants manufacturers to cut the sugar used in nine product areas by a fifth by 2020, with a 5% cut in the current year.

Stephen O’Hara, Optibiotix’s chief executive, believes Sweetbiotix, a naturally sweet fibre it is developing, may be the answer.

He told Proactive: “We are creating sugars that act as fibres, but have no calories and don’t add to obesity.”

Public Health England said it wanted food makers to reformulate products to lower the levels of sugar present; reduce the portion size and calories in servings and also push customers towards lower or no added sugar products.

O’Hara suggests its Sweetbiotix product has the capability to cover all of these issues while also strengthening the body’s  microbiome, the mass of microbes that carry out essential functions such as breaking down food and fighting off infections.

The government’s initiative has been a great opportunity to remind markets we are working in this area  and may be able to launch our first sweet healthy fibre either later this year or early next, he said.

Unlike other products, (such as plant extract stevia)  O’Hara says there will be no taste trade-off.

“We are focused on natural fibres that are healthy and have an intrinsic sweetness.

“Sweetbiotix is a healthy sweetener rather than a replacement sweetener.”

]]>
Mon, 03 Apr 2017 15:21:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/175862/optibiotix-sees-great-opportunity-in-government-s-sugar-reduction-drive-175862.html